Browse regulations

Regulation establishes detailed lender participation rules for HUD's Section 184 loan guarantee program for Native American housing on tribal lands, including approval processes, quality control, reporting, and compliance standards.

This racially discriminatory federal program violates equal protection, imposes massive compliance costs that inflate housing expenses, creates moral hazard through loan guarantees exposing taxpayers to losses, and represents unconstitutional federal intrusion into tribal affairs better handled by tribal sovereignty or market solutions.

This regulation governs the Tribal Transportation Facility Bridge Program (TTFBP), a federal grant program providing funds to tribal governments for bridge construction, rehabilitation, and related activities on tribal transportation facilities. It establishes eligibility criteria (bridges in poor condition, low load capacity, or needing geometric improvements), prioritization rules based on condition ratings, school bus routes, and traffic volumes, and detailed application procedures requiring submission of specific documentation to the FHWA. The program allocates funding between planning/engineering and construction, and between BIA/Tribally owned versus non-Tribally owned bridges, with provisions for cost overruns and excess fund recovery.

This program federalizes what should be sovereign tribal infrastructure decisions, imposing bureaucratic oversight, compliance costs, and federal prioritization criteria that distort tribal incentives and erode self-determination. The administrative overhead and mandated federal standards create unseen burdens on tribes while the funds could be provided via block grants without micromanagement, allowing tribes to allocate resources according to their own priorities. The program exemplifies inappropriate federal expansion into areas reserved to tribes under principles of constitutional federalism.

Regulation establishes FHWA approval process for any changes to Interstate System access points. Requires states to submit detailed technical reports demonstrating safety, operations, and engineering compliance. Provides narrow exceptions for specific facilities and allows programmatic agreements delegating review authority to states.

Federal micromanagement of local transportation infrastructure. The $2-trillion regulatory burden includes this bureaucratic layer that slows highway improvements, imposes one-size-fits-all engineering standards on diverse local conditions, and forces states to navigate complex federal processes for modifications to roads they maintain. The Interstate System is aging and needs flexibility—this rule treats it as a sacred relic rather than a productive asset. States should control access to their highways; federal review serves only to protect bureaucratic turf and delay projects that would alleviate congestion. The exceptions prove the rule's overbreadth—why prohibit private access connections or partial interchanges unless regulators know better than local officials? Eliminate this process, return authority to states, and let transportation emerge from local needs rather than Washington's engineering dogma.

This regulation ensures USAID does not discriminate against faith-based organizations in award decisions and protects against use of federal funds for explicitly religious activities, while allowing religious organizations to maintain their religious character and receive accommodations for religious exercise.

Without this rule, faith-based organizations could face discrimination in federal foreign aid programs, excluding many effective NGOs from vital humanitarian and development work. The regulation prevents a theocratic monopoly in aid distribution while maintaining constitutional church-state boundaries, achieving religious liberty that would be difficult to guarantee without explicit guidance to bureaucrats.

Establishes complete immunity from US criminal, civil, and administrative jurisdiction for foreign diplomatic agents, certain consular/administrative staff, and other designated foreign officials as determined by the Department of State, in accordance with the Vienna Convention and international agreements.

Repealing this would eliminate the reciprocal protection for US diplomats abroad, invite retaliation against American officials, violate international treaty obligations, and cripple America's ability to conduct diplomacy and protect its citizens overseas. The regime achieves vital national security interests through a globally-established framework that cannot be replaced without compromising US sovereignty and personnel safety.

FDA's Quality System Regulation for medical devices, incorporating ISO 13485 with added requirements for unique device identification, complaint handling, and labeling controls to ensure safety and effectiveness throughout manufacturing and distribution.

Compliance imposes massive hidden costs on healthcare, inflating prices and limiting access, especially harming small manufacturers and startups. Regulatory capture protects incumbents. Unseen consequences include delayed innovation, reduced competition, and higher overall healthcare spending. Market-based alternatives (third-party certification, tort liability, insurer standards) can achieve safety without bureaucratic rigidity.

This FDA regulation (21 CFR Part 230) establishes the certification process for 'designated medical gases'—a streamlined alternative to full premarket approval for certain medical gases like oxygen, nitrogen, and carbon dioxide. It requires certification applications, annual reports, postmarketing safety reporting (including Individual Case Safety Reports), field alerts for quality issues, and maintenance of records. FDA review occurs within 60 days, after which certification is 'deemed granted' unless denied. The regulation includes provisions for amendments, supplements, ownership transfers, and withdrawal/revocation procedures.

Medical gases are life-critical products where contamination, incorrect composition, or labeling errors can cause immediate death or serious injury. The certification process provides a minimal but essential federal safety net: verifying that manufacturers meet compendial standards, maintain adequate facilities, and promptly report adverse events and quality problems. Without this, patients would rely solely on state tort law and market forces—inadequate remedies when gases are mistakenly contaminated or mislabeled at the point of manufacture. The stream-lined approach (versus full drug approval) acknowledges these products' long safety history while ensuring traceability and surveillance. Deleting it would remove the only systematic federal oversight of a product category that crosses state lines and serves vulnerable patients in hospitals, homes, and emergency settings.

FDA regulation establishing current good manufacturing practice (CGMP) requirements for medical gases. Covers quality units, personnel training, facilities, equipment, production and process controls, labeling, laboratory controls, stability testing, and documentation. Applies to manufacturers, processors, packers, and holders of medical gases as defined by the FD&C Act.

Keeping this regulation imposes massive hidden taxes through compliance costs, disproportionately harming small medical gas producers and raising healthcare costs. It represents unconstitutional federal overreach into manufacturing—a state police power under the Tenth Amendment. The prescriptive rules create barriers to entry that protect incumbents, stifle innovation, and divert resources from genuine quality to box-ticking compliance.

21 CFR § 202.1 governs prescription drug advertising, requiring that ads include a 'brief summary' of side effects/contraindications in 'fair balance' with effectiveness claims, established names must accompany proprietary names in specified type sizes, and enumerates extensive rules about what constitutes false/misleading advertising including specific provisions for broadcast ads requiring dual-modality presentation of risks.

This regulation censors commercial speech about pharmaceuticals, imposing $2 trillion+ in annual compliance costs that punish small businesses and raise drug prices for families. The FDA's 'fair balance' doctrine allows bureaucrats to dictate narrative content and formatting, violating the First Amendment. The 185,000-page CFR labyrinth makes compliance impossible to navigate, violating rule of law. Hidden tax exceeds $14,000 per household annually. The regulation protects incumbent drug companies through barriers to entry while distorting market information flow—Hayek's knowledge problem makes central planners ill-suited to determine 'appropriate' medical communications. State tort law and FTC false advertising rules already address fraud without this federal overreach.

This regulation establishes SSA's detailed procedures for implementing FOIA, covering request requirements, fee structures, processing timelines, exemptions, appeals, and proactive disclosure of records.

The regulation creates a costly administrative apparatus (FOIA officers, liaisons, complex fee calculations, and multi-tiered appeals) that diverts taxpayer resources from SSA's core mission. Its intricate requirements deter legitimate requests, impose hidden compliance costs, and contribute to the regulatory burden without proportionate transparency benefits. Simpler, proactive disclosure would achieve FOIA's goals at far lower cost.

Prohibits futures brokers from trading against customer orders, front-running, disclosing orders, and taking the other side without consent. Requires internal controls and recordkeeping. Broadly defines 'affiliated persons' to include family members and monitors cross-firm accounts.

Prevents fraud and conflicts of interest that would erode trust in futures markets, impairing price discovery and risk management. These conduct rules are essential given information asymmetries; private enforcement alone would be inadequate due to detection difficulties.

This regulation (17 CFR Part 145) implements the Freedom of Information Act (FOIA) at the Commodity Futures Trading Commission (CFTC). It establishes procedures for public access to agency records, defines public vs. nonpublic records, outlines request requirements, fee structures, appeal processes, and procedures for requesting confidential treatment of submitted commercial information. It applies nine FOIA exemptions to withhold records, including trade secrets, personal privacy, law enforcement records, and privileged intra-agency memoranda.

This regulation implements a clear congressional mandate (FOIA) that promotes transparency and democratic accountability. The compliance costs represent the legitimate price of ensuring government actions are knowable and subject to public scrutiny—a foundational requirement for liberty. The structured procedures reduce arbitrary agency power, prevent regulatory capture by enabling external oversight, and provide predictability that actually lowers compliance uncertainty for all market participants, particularly small businesses. Removing it would undermine the rule of law principle that government must operate in sunlight, not eliminate the underlying statutory obligation.

This CFTC regulation governs 'leverage contracts'—long-term (10+ year) leveraged contracts for gold, silver, or platinum where customers post margin and pay carrying charges, with physical delivery upon satisfaction. The rule requires registration of both leverage transaction merchants and each specific commodity, imposes 90% 'cover' requirements (physical or financial backing), minimum capital standards, extensive reporting, and detailed operational rules to prevent fraud in these niche financial products.

The regulation imposes crushing compliance burdens on an extremely niche market for the sole purpose of fraud prevention. General anti-fraud laws already apply, making these specialized rules redundant. The 90% cover requirement and registration costs create prohibitive barriers to entry, protecting large incumbent firms while stifling competition and innovation. These are sophisticated, voluntary transactions between consenting adults who should be free to assume investment risk. The unseen costs—reduced market participation, higher prices, and lost financial innovation—far outweigh any marginal fraud prevention benefit in this tiny corner of the commodities market.

This regulation requires traders with reportable futures/options positions to file detailed Form 40 reports with the CFTC upon special call, disclosing daily position data, account structures, ownership, control relationships, business purposes for trading, and affiliations. It mandates ongoing record-keeping and updates, covering both proprietary and client trading activities across U.S. and foreign markets.

The reporting burden imposes massive compliance costs and creates a surveillance state atmosphere, violating privacy and commercial confidentiality. The special call mechanism grants overly broad discretionary power, distorting market incentives and potentially driving trading offshore. CFTC cannot effectively process this data to prevent manipulation, which markets and exchanges can police better themselves. The regulation raises barriers to entry and exemplifies the knowledge problem—bureaucrats cannot centrally understand complex market relationships. Any legitimate fraud or manipulation concerns can be addressed through targeted law enforcement, not blanket reporting mandates.

Daily reporting requirement for futures brokers to submit detailed position data on 'special accounts' (large trader accounts) to CFTC, including all futures/options positions, trades, deliveries, exercises, and assignments. Must be filed electronically by 9 a.m. next business day with Form 102 identification and periodic updates.

Imposes heavy compliance costs on all brokers, with small firms bearing 30% higher per-employee burden. Creates government database of private trading positions, violating privacy and distorting market behavior through surveillance. Unseen costs include account-splitting that fragments liquidity, barriers to entry protecting incumbents, and deadweight loss from diverted resources. The marginal benefit in detecting manipulation is questionable given exchanges already monitor activity; this serves bureaucratic expansion more than market integrity.